Literature DB >> 4046972

The use of chemotherapy for extraocular retinoblastoma.

C B Pratt, D B Crom, C Howarth.   

Abstract

Among the 114 children with retinoblastoma seen at St. Jude Children's Research Hospital 1962-1984, 11 have received treatment with chemotherapy for measurable extraocular disease which was present at diagnosis (seven patients) or developed later during the subsequent course of their disease (four patients). Metastatic disease involved the brain and spinal fluid of four persons, the orbit of five, the bone marrow of five, lymph nodes of four, and soft tissues of three individuals at the time of their treatments. Single agents or combinations were used. Two patients with orbital extension of primary retinoblastoma developed complete responses following chemotherapy and subsequently received orbital irradiation, and have had long-term disease-free survival. Additional responses developed in patients who received vincristine, cyclophosphamide, adriamycin, cisplatin, VM-26, and ifosfamide, singly or in combination. With future identification of effective chemotherapy, new studies may be focused upon patients with localized disease to reduce radiation dosage or the need for immediate surgical resection of all involved eyes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4046972     DOI: 10.1002/mpo.2950130606

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  4 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Retinoblastoma in Taiwan: survival rate and prognostic factors.

Authors:  Chia-Yau Chang; Tzeon-Jye Chiou; Betau Hwang; Li-Yuan Bai; Wen-Ming Hsu; Yuh-Lin Hsieh
Journal:  Jpn J Ophthalmol       Date:  2006 May-Jun       Impact factor: 2.447

3.  Neoadjuvant chemotherapy for extensive unilateral retinoblastoma.

Authors:  E Bellaton; A I Bertozzi; C Behar; P Chastagner; H Brisse; C Sainte-Rose; F Doz; L Desjardins
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

Review 4.  Orbital retinoblastoma: An update.

Authors:  Santosh G Honavar; Fairooz P Manjandavida; Vijay Anand P Reddy
Journal:  Indian J Ophthalmol       Date:  2017-06       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.